Impaired renal function predicts short term prognosis in patients with acute pulmonary embolism

Similar documents
DECLARATION OF CONFLICT OF INTEREST

Plasma MR-proADM is superior to NTproBNP for all-cause short term mortality prediction in acute pulmonary embolism.

ORIGINAL ARTICLE. Department of Internal Medicine and Cardiology, The Medical University of Warsaw, Poland

RISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM. David Jiménez, MD, PhD, FCCP Ramón y Cajal Hospital, IRYCIS Madrid, Spain

Ryan Walsh, MD Department of Emergency Medicine Madigan Army Medical Center

Biomarker-based risk assessment model in acute pulmonary embolism

The spectrum of clinical outcome of PE

Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction

Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD

C. Michael Gibson, M.S., M.D. Professor of Medicine Harvard Medical School

Acute and long-term treatment of PE. Cecilia Becattini University of Perugia

Acute and long-term treatment of VTE. Cecilia Becattini University of Perugia

The shock index and the simplified PESI for identification of low-risk patients with acute pulmonary embolism

Cardiorenal Syndrome

Early risk stratification is essential in the management of

ORIGINAL INVESTIGATION

Management of Intermediate-Risk Pulmonary Embolism

Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)

How to manage ACS patients with Comorbidities? Patients with Renal Failure

Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model

Mario Plebani University-Hospital of Padova, Italy

How will new high sensitive troponins affect the criteria?

N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism

Troponin when is an assay high sensitive?

Disclosures. Objectives

Troponin I and risk stratification of patients with acute nonmassive pulmonary embolism

Updates in venous thromboembolism. Cecilia Becattini University of Perugia

Post-Procedural Myocardial Injury or Infarction

Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?

Masatoshi Kawashima 1, Koji Wada 2, Hiroshi Ohta 2, Rika Moriya 3 and Yoshiharu Aizawa 1. Journal of Occupational Health

Management of Massive and Sub-Massive Pulmonary Embolism

Ischemic and bleeding risk stratification in NSTE ACS. Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland

Massive and Submassive Pulmonary Embolism: 2017 Update and Future Directions

Risk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium

High Sensitivity Troponin Improves Management. But Not Yet

Duration of Therapy for Venous Thromboembolism

Troponin Assessment. Does it Carry Clinical Message? Stefan Blankenberg. University Heart Center Hamburg

MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC

Screening and early recognition of CKD. John Ngigi (FISN) Kidney specialist

Supplemental Material. Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present

Anticoagulation: Novel Agents

Single-Center, Retrospective, Observational Analysis of Patients with Submassive Pulmonary Embolism (PE) Receiving Catheter- Directed Thrombolysis

Age-adjusted hstnt cut-off value for risk stratification of pulmonary embolism

Timing of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism

Is it safe to manage pulmonary embolism in Primary Care? Roopen Arya King s College Hospital

Epidemiology. Update on Pulmonary Embolism. Keys to PE Management 5/5/2014. Diagnosis. Risk stratification. Treatment

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective

E.Ritz Heidelberg (Germany)

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension*

UC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE

Supplementary Online Content

CVD risk assessment using risk scores in primary and secondary prevention

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

Pulmonary embolism: Acute management. Cecilia Becattini University of Perugia, Italy

Obesity, renal failure, HIT: which anticoagulant to use?

EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS

Cardiopulmonary Imaging Original Research

Impact of Renal Dysfunction on the Outcome of Acute Myocardial Infarction

Cardiac troponin I for predicting right ventricular dysfunction and intermediate risk in patients with normotensive pulmonary embolism

Timing of angiography for high- risk ACS

The Triple Threat. Cardiac Care in the NT Annual Workshop 2017 is proudly supported by:

CATH LAB SYMPOSIUM 2010

A New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta

Antithrombotics in Stroke management

Insufficienza renale e DOAC

The Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?

What s new with DOACs? Defining place in therapy for edoxaban &

Aortic Stenosis in the Elderly: Difficulties for the Clinician. Are Symptoms Due to Aortic Stenosis?

Medical Patients: A Population at Risk

TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS

Pulmonary Embolectomy:

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease

Principal Equations of Dialysis. John A. Sweeny

Optimal Management of Intermediate-Risk Pulmonary Embolism

ORIGINAL INVESTIGATION. Thrombolysis vs Heparin in the Treatment of Pulmonary Embolism

Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY

Optimal Use of Iodinated Contrast Media In Oncology Patients. Focus on CI-AKI & cancer patient management

Measuring Natriuretic Peptides in Acute Coronary Syndromes

Contrast-Induced Nephropathy: Evidenced Based Prevention

Age adjusted plasma D dimer levels in suspected acute pulmonary embolism: a retrospective, single center study

Evidences for real-life use in fragile patients: Renal failure and cancer

What is New in Acute Pulmonary Embolism? Interventional Treatment. Prof. Nils Kucher University Hospital Bern Switzerland

ACUTE CORONARY SYNDROME PCI IN THE ELDERLY

DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center

S (18) doi: /j.ajem Reference: YAJEM 57346

Lucia Cea Soriano 1, Saga Johansson 2, Bergur Stefansson 2 and Luis A García Rodríguez 1*

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

DALLA REAL LIFE INTERNAZIONALE A QUELLA ITALIANA: ESPERIENZE DAL CAMPO

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)

Dolore Toracico e Livelli di Troponina non Misurabili

Journal of the American College of Cardiology Vol. 45, No. 11, by the American College of Cardiology Foundation ISSN /05/$30.

VENOUS THROMBOEMBOLISM, CANCER AND CKD ANOTHER TRIAD TO MANAGE

Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

NOAC: Future perspectives: academic perspective. Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands

Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?

Two: Chronic kidney disease identified in the claims data. Chapter

Introduction to Clinical Diagnosis Nephrology

Outcome of patients with right heart thrombi: the Right Heart Thrombi European Registry

Transcription:

Impaired renal function predicts short term prognosis in patients with acute pulmonary embolism Kostrubiec Maciej, Łabyk Andrzej, Pedowska-Włoszek Jusyna, Pacho Szymon, Jankowski Krzysztof, Koczaj-Bremer Magdalena, Dul Paweł, Wojciechowski Artur, Pruszczyk Piotr The Medical University of Warsaw, Poland

Introduction Torbicki et al. EHJ 2008

Introduction Glomerular filtration rate (GFR) is one of the generally accepted indicators of increased mortality in various cardiovascular diseases like: acute coronary syndromes (included into the GRACE risk scale) heart failure Al Suwaidi J et al. Circulation 2002; 106: 974 80. Gibson CM et al. J Am Coll Cardiol 2003; 42: 1535 43. Granger CB et al. Arch Intern Med 2003; 163: 2345 53. Damman K eta al. J Card Fail 2007; 13: 599 608.

Introduction ICOPER registry - creatinine concentration> 177 umol/l predicted 3-month mortality [1] Renal insufficiency (creatinine >2 mg/dl) predicted death within 7 days with an odds ratio (OR) of 2.66 in univariate analysis (in the multivariatemodel p=0.07) [2] Renal failure predicted 40-day all-casue moratlity HR 6.43 95% (CI:2.22 18.61 p=0.002) in univariate analysis [3] RIETE registry - 1037 of the 18 251 (5.7%) pts with VTE had a Cr clearance <30 ml/min during the 3-month observation - increased incidence of fatal bleeding, fatal PE and all-cause death [4] 1) Goldhaber SZ et al. Lancet 1999; 353: 1386 9 2) Conget F et al. Thromb Haemost 2008; 100: 937 42 3) Kostrubiec M et al. Eur Heart J 2005; 26: 2166 72 4) Falga C et al. Thromb Haemost 2007; 98: 771 6.

Hypothesis Renal dysfunction is an independent marker of early mortality in APE And renal function assessment may improve troponin-based risk stratification

Methods Inclusion criteria: age > 18 yrs acute pulmonary embolism (APE) - proven by spiral CT End point: 30-day all-cause mortality

Methods On admission blood samples were obtained for: creatinine ctnt (Roche, ECLIA) and ctni (Dimension RxL, Dade Behring) GFR was estimated using the Modification of Diet in Renal Disease (MDRD) formula. GFR= 186 (Scr)1.154 Age)0.203 (0.742 if female) (1.210 if African-American) where serum creatinine (Scr) is measured in milligram per deciliter and age in years

Material 220 consecutive pts with APE (86M, 134F) mean age 64±18 yrs

Clinical characteristic 8 pts with high-risk PE 131 pts with moderate-risk PE 81 pts with low-risk PE 212 pts

Clinical outcome 23 (10%) of pts died by 30th day of observation 17 (8%) APE-related deaths (clinically diagnosed irreversible RV insufficiency or recurrent PE) 4 deaths in the high-risk APE (all cause/ape mortality 50%/50%) 18 fatal cases in moderate-risk PE (14%/11%) 1 death in low-risk APE (1%/1%)

Results Impaired renal function in 47% pts with APE (GFR <60 ml/min)

Results Glomerular filtration rate (GFR) values in non-survivors and survivors

Results ROC curve of GFR for predicting 30-day mortality in all APE pts GFR<35 ml/min GFR<35ml/min was in 32 (15%) pts sensitivity 52%, specificity 90%, PPV 38% NPV 94% for prediction of death within 30 days after admission In pts with GFR<35ml/min: 10 APE-related deaths and 2 deaths related to major bleeding; however, both patients with fatal hemorrhage had elevated ctn and echocardiographic signs of RV dysfunction

Results Comparison of ROC curves for GFR and ctn in pts with non-high-risk APE

Results Cumulative 30-day survival (Kaplan Meier) of 212 pts with non-high-risk APE, according to GFR and troponin independent mortality predictors for 30-day allcause mortality: GFR (HR 1.46, CI95%:1.11 1.92, per 10 ml/min decrease, p<0.01), positive troponin (HR 14.1, CI95%:1.4 37.6; p=0.02), increased heart rate (HR 1.31, CI95%:1.07 1.61; per 10 beats, p<0.01) history of CHF (HR 4.9, CI95%:1.9 12.4; p=0.001)

Conclusion Impaired kidney function, present in 47% of APE patients, is related to all-cause mortality. In initially normotensive patients, a GFR<35mL/min predicts 30-day mortality. Moreover, GFR assessment can improve troponin-based risk stratification of APE.

Acute Pulmonary Embolism Acute or Chronic Kidney Dysfunction?

N-GAL, marker of acute kidney injury, in patients with APE 220 200 180 p<0.05 160 140 78(48-200) N-GAL [ng/ml] 120 100 80 60 40 20 0-20 53(15-199) 56(7-200) low risk moderate risk high risk Mediana 25%-75% Min-Maks N-GAL [ng/ml] 220 200 180 160 140 120 100 80 p<0.02 86(39-200) 60 55(7-200) N-GAL>75ng/ml in 30% of pts 40 20 0-20 survivors non-survivors Mediana 25%-75% Min-Maks